Median Technologies strengthens its position with pharmaceutical giants

On May 21, 2024, Median Technologies, specialized in imaging services for clinical trials in oncology, announced its partnership with a new pharmaceutical laboratory member of the Top 3 worldwide.

With this new agreement, Median becomes the preferred supplier of two of the three largest global laboratories, dominant in terms of revenue in oncology. The contract concerns late-phase clinical trials requiring centralized image reading.

This partnership confirms Median's ability to offer high quality services in the clinical trials sector, particularly in the United States. Using artificial intelligence-based technologies, the company optimizes the operations of its pharmaceutical clients and improves their growth prospects.